Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: Correlations with neutralizing antibodies and cytotoxic T cells

Gerald V. Quinnan, Xiao Fang Yu, Mark G. Lewis, Fei Zhang Peng, Gerd Sutter, Peter Silvera, Ming Dong, Anil Choudhary, Phuong T N Sarkis, Peter Bouma, Zhiqiang Zhang, David C. Montefiori, Thomas C. VanCott, Christopher C. Broder

Research output: Contribution to journalArticle

Abstract

We studied the capacity of active immunization of rhesus monkeys with HIV-1 envelope protein (Env) to induce primary virus cross-reactive neutralizing antibodies to prevent infection following intravenous challenge with simian-human immunodeficiency virus (SHIV). Monkeys were immunized with the human immunodeficiency type 1 (HIV-1) strain R2 Env. Initially, the Env was expressed in vivo by an alphavirus replicon particle system, and then it was administered as soluble oligomeric gp140. Concurrently, groups of monkeys received expression vectors that encoded either simian immunodeficiency virus (SIV) gag/pol genes or no SIV genes in vivo to test the additional protective benefit of concurrent induction of virus-specific cell-mediated immune (CMI) responses. Groups of control monkeys received either the gag/pol regimen or sham immunizations. The antibodies induced by the Env immunization regimen neutralized diverse primary HIV-1 strains. Similarly, potent CMI responses were induced by the gag/pol regimen, as measured by gamma interferon enzyme-linked immunospot assays. Differences in the responses among groups of monkeys strongly suggested that there was interference between the Env and gag/pol immunization regimens. Complete protection of some of the monkeys against infection after intravenous challenge with the partially pathogenic SHIV DH12R (Clone 7) was associated independently with both neutralizing antibody and CMI responses. Protection was associated with SHIV DH12(Clone7) serum neutralizing antibody titers of ≥1:80 or with cellular immune responses corresponding to >2,000 spot forming cells per 106 peripheral blood mononuclear cells. Immunization was also associated with a reduction in the magnitude and duration of virus load. Induction of cross-reactive, primary HIV-1-neutralizing antibodies is feasible and, when potent, may result in complete protection against infection with a heterologous challenge virus strain.

Original languageEnglish (US)
Pages (from-to)3358-3369
Number of pages12
JournalJournal of Virology
Volume79
Issue number6
DOIs
StatePublished - Mar 2005

Fingerprint

Simian Immunodeficiency Virus
Human immunodeficiency virus
Macaca mulatta
Neutralizing Antibodies
neutralizing antibodies
Haplorhini
monkeys
immunization
Human immunodeficiency virus 1
T-lymphocytes
cell-mediated immunity
HIV
HIV-1
Immunization
T-Lymphocytes
Simian immunodeficiency virus
Infection
infection
Viruses
viruses

ASJC Scopus subject areas

  • Immunology

Cite this

Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus : Correlations with neutralizing antibodies and cytotoxic T cells. / Quinnan, Gerald V.; Yu, Xiao Fang; Lewis, Mark G.; Peng, Fei Zhang; Sutter, Gerd; Silvera, Peter; Dong, Ming; Choudhary, Anil; Sarkis, Phuong T N; Bouma, Peter; Zhang, Zhiqiang; Montefiori, David C.; VanCott, Thomas C.; Broder, Christopher C.

In: Journal of Virology, Vol. 79, No. 6, 03.2005, p. 3358-3369.

Research output: Contribution to journalArticle

Quinnan, GV, Yu, XF, Lewis, MG, Peng, FZ, Sutter, G, Silvera, P, Dong, M, Choudhary, A, Sarkis, PTN, Bouma, P, Zhang, Z, Montefiori, DC, VanCott, TC & Broder, CC 2005, 'Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: Correlations with neutralizing antibodies and cytotoxic T cells', Journal of Virology, vol. 79, no. 6, pp. 3358-3369. https://doi.org/10.1128/JVI.79.6.3358-3369.2005
Quinnan, Gerald V. ; Yu, Xiao Fang ; Lewis, Mark G. ; Peng, Fei Zhang ; Sutter, Gerd ; Silvera, Peter ; Dong, Ming ; Choudhary, Anil ; Sarkis, Phuong T N ; Bouma, Peter ; Zhang, Zhiqiang ; Montefiori, David C. ; VanCott, Thomas C. ; Broder, Christopher C. / Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus : Correlations with neutralizing antibodies and cytotoxic T cells. In: Journal of Virology. 2005 ; Vol. 79, No. 6. pp. 3358-3369.
@article{90330fa307e64a7b85e82c7bfe865206,
title = "Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: Correlations with neutralizing antibodies and cytotoxic T cells",
abstract = "We studied the capacity of active immunization of rhesus monkeys with HIV-1 envelope protein (Env) to induce primary virus cross-reactive neutralizing antibodies to prevent infection following intravenous challenge with simian-human immunodeficiency virus (SHIV). Monkeys were immunized with the human immunodeficiency type 1 (HIV-1) strain R2 Env. Initially, the Env was expressed in vivo by an alphavirus replicon particle system, and then it was administered as soluble oligomeric gp140. Concurrently, groups of monkeys received expression vectors that encoded either simian immunodeficiency virus (SIV) gag/pol genes or no SIV genes in vivo to test the additional protective benefit of concurrent induction of virus-specific cell-mediated immune (CMI) responses. Groups of control monkeys received either the gag/pol regimen or sham immunizations. The antibodies induced by the Env immunization regimen neutralized diverse primary HIV-1 strains. Similarly, potent CMI responses were induced by the gag/pol regimen, as measured by gamma interferon enzyme-linked immunospot assays. Differences in the responses among groups of monkeys strongly suggested that there was interference between the Env and gag/pol immunization regimens. Complete protection of some of the monkeys against infection after intravenous challenge with the partially pathogenic SHIV DH12R (Clone 7) was associated independently with both neutralizing antibody and CMI responses. Protection was associated with SHIV DH12(Clone7) serum neutralizing antibody titers of ≥1:80 or with cellular immune responses corresponding to >2,000 spot forming cells per 106 peripheral blood mononuclear cells. Immunization was also associated with a reduction in the magnitude and duration of virus load. Induction of cross-reactive, primary HIV-1-neutralizing antibodies is feasible and, when potent, may result in complete protection against infection with a heterologous challenge virus strain.",
author = "Quinnan, {Gerald V.} and Yu, {Xiao Fang} and Lewis, {Mark G.} and Peng, {Fei Zhang} and Gerd Sutter and Peter Silvera and Ming Dong and Anil Choudhary and Sarkis, {Phuong T N} and Peter Bouma and Zhiqiang Zhang and Montefiori, {David C.} and VanCott, {Thomas C.} and Broder, {Christopher C.}",
year = "2005",
month = "3",
doi = "10.1128/JVI.79.6.3358-3369.2005",
language = "English (US)",
volume = "79",
pages = "3358--3369",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus

T2 - Correlations with neutralizing antibodies and cytotoxic T cells

AU - Quinnan, Gerald V.

AU - Yu, Xiao Fang

AU - Lewis, Mark G.

AU - Peng, Fei Zhang

AU - Sutter, Gerd

AU - Silvera, Peter

AU - Dong, Ming

AU - Choudhary, Anil

AU - Sarkis, Phuong T N

AU - Bouma, Peter

AU - Zhang, Zhiqiang

AU - Montefiori, David C.

AU - VanCott, Thomas C.

AU - Broder, Christopher C.

PY - 2005/3

Y1 - 2005/3

N2 - We studied the capacity of active immunization of rhesus monkeys with HIV-1 envelope protein (Env) to induce primary virus cross-reactive neutralizing antibodies to prevent infection following intravenous challenge with simian-human immunodeficiency virus (SHIV). Monkeys were immunized with the human immunodeficiency type 1 (HIV-1) strain R2 Env. Initially, the Env was expressed in vivo by an alphavirus replicon particle system, and then it was administered as soluble oligomeric gp140. Concurrently, groups of monkeys received expression vectors that encoded either simian immunodeficiency virus (SIV) gag/pol genes or no SIV genes in vivo to test the additional protective benefit of concurrent induction of virus-specific cell-mediated immune (CMI) responses. Groups of control monkeys received either the gag/pol regimen or sham immunizations. The antibodies induced by the Env immunization regimen neutralized diverse primary HIV-1 strains. Similarly, potent CMI responses were induced by the gag/pol regimen, as measured by gamma interferon enzyme-linked immunospot assays. Differences in the responses among groups of monkeys strongly suggested that there was interference between the Env and gag/pol immunization regimens. Complete protection of some of the monkeys against infection after intravenous challenge with the partially pathogenic SHIV DH12R (Clone 7) was associated independently with both neutralizing antibody and CMI responses. Protection was associated with SHIV DH12(Clone7) serum neutralizing antibody titers of ≥1:80 or with cellular immune responses corresponding to >2,000 spot forming cells per 106 peripheral blood mononuclear cells. Immunization was also associated with a reduction in the magnitude and duration of virus load. Induction of cross-reactive, primary HIV-1-neutralizing antibodies is feasible and, when potent, may result in complete protection against infection with a heterologous challenge virus strain.

AB - We studied the capacity of active immunization of rhesus monkeys with HIV-1 envelope protein (Env) to induce primary virus cross-reactive neutralizing antibodies to prevent infection following intravenous challenge with simian-human immunodeficiency virus (SHIV). Monkeys were immunized with the human immunodeficiency type 1 (HIV-1) strain R2 Env. Initially, the Env was expressed in vivo by an alphavirus replicon particle system, and then it was administered as soluble oligomeric gp140. Concurrently, groups of monkeys received expression vectors that encoded either simian immunodeficiency virus (SIV) gag/pol genes or no SIV genes in vivo to test the additional protective benefit of concurrent induction of virus-specific cell-mediated immune (CMI) responses. Groups of control monkeys received either the gag/pol regimen or sham immunizations. The antibodies induced by the Env immunization regimen neutralized diverse primary HIV-1 strains. Similarly, potent CMI responses were induced by the gag/pol regimen, as measured by gamma interferon enzyme-linked immunospot assays. Differences in the responses among groups of monkeys strongly suggested that there was interference between the Env and gag/pol immunization regimens. Complete protection of some of the monkeys against infection after intravenous challenge with the partially pathogenic SHIV DH12R (Clone 7) was associated independently with both neutralizing antibody and CMI responses. Protection was associated with SHIV DH12(Clone7) serum neutralizing antibody titers of ≥1:80 or with cellular immune responses corresponding to >2,000 spot forming cells per 106 peripheral blood mononuclear cells. Immunization was also associated with a reduction in the magnitude and duration of virus load. Induction of cross-reactive, primary HIV-1-neutralizing antibodies is feasible and, when potent, may result in complete protection against infection with a heterologous challenge virus strain.

UR - http://www.scopus.com/inward/record.url?scp=20044393036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044393036&partnerID=8YFLogxK

U2 - 10.1128/JVI.79.6.3358-3369.2005

DO - 10.1128/JVI.79.6.3358-3369.2005

M3 - Article

C2 - 15731230

AN - SCOPUS:20044393036

VL - 79

SP - 3358

EP - 3369

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 6

ER -